The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

In contrast, we discovered new potential prognostic factors for these patients: the combination of t(4;14) plus FGFR3 mutation, as well as NRAS mutations, were both significantly associated with lower bPFS rates in univariate analyses; conversely, patients with KRAS mutations showed a trend towards longer bPFS (Fig. 4A-C ).

also in 53,322 other papers

TRAF3 mutations did not reach statistical significance, probably given the short size of the UHR MM subset, but in the MMRF’s CoMMpass cohort their presence predicted significantly improved outcomes as compared to TRAF3 wild-type patients (Fig. 5A-C ).

also in 111,027 other papers